Routine annual meeting filing with no surprises. The increased share reserve for equity compensation is standard practice and does not signal any change in business outlook. Monitor next quarterly earnings for operational performance.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $82.72entry
- T+1 · 6mo ago −1.58%α −2.17% · $81.41
- T+5 · 6mo ago −7.27%α −8.92% · $76.71
- T+20 · 5mo ago −2.54%α −1.12% · $80.62
- T+60 · 3mo ago −7.07%α −10.26% · $76.87
Price Chart
How similar events traded
Executive Summary
ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees were elected, Ernst & Young was ratified as auditor, say-on-pay was approved on an advisory basis, and stockholders approved the Amended and Restated 2022 Stock Incentive Plan. The plan adds up to 962,000 new shares to the existing reserve, bringing the total authorized pool to 8,222,000 shares. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the Amended and Restated 2022 Stock Incentive Plan, increasing the share reserve by up to 962,000 shares to a total of 8,222,000 shares.
- All seven director nominees were elected with strong support (lowest 'for' vote was 14,063,620 for Renee P. Tannenbaum).
- Ernst & Young LLP was ratified as independent auditor for FY2026 with 16,874,103 votes in favor.
- Say-on-pay was approved on an advisory basis (13,819,988 for, 1,058,460 against).
- Stockholders voted for an annual frequency for future say-on-pay advisory votes.
- No officer departures, appointments, or material compensation changes were reported.
Financial Impact
No material financial impact. The stock plan amendment authorizes up to 962,000 additional shares, representing approximately 4.2% of the 22,750,198 common shares outstanding as of the record date.
Risk Factors
- Potential future dilution from equity grants under the expanded plan, though this is typical for a pharmaceutical company.
- Say-on-pay opposition of ~7% (1,058,460 against out of 14,895,825 votes cast) is modest and not a red flag.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000056 |
| Document: ani-20260521.htm | 0001023024-26-000056 |
| Document: 0001023024-26-000056-index-headers.html | 0001023024-26-000056 |
| Document: 0001023024-26-000056-index.html | 0001023024-26-000056 |
| Document: 0001023024-26-000056.txt | 0001023024-26-000056 |
Track record
34 reports on ANIP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers